Business
NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock.
About this update from Niobay Metals Inc.
[{"type":"text","content":"\n\n\n\nEMERYVILLE, CA, Oct. 31 /CNW/ - NovaBay Pharmaceuticals, Inc. (AMEX, TSX:\nNBY) today announced the closing of its initial public offering of 5,000,000\nshares of its common stock at a price to the public of U.S.$4.00 per share.\nNovaBay has granted to the underwriters a 30-day option to purchase up to an\nadditional 750,000 shares at the initial public offering price to cover\nover-allotments, if any. The shares are trading on the American Stock Exchange\nand the Toronto Stock Exchange under the symbol "NBY".\n\n\nDundee Securities Corporation acted as the sole book runner for the\noffering, with Desjardins Securities Inc. as co-lead manager. The shares were\noffered in Canada by an underwriting syndicate co-led by Dundee Securities\nCorporation and Desjardins Securities Inc. and including Blackmont Capital\nInc., and in the United States by Dundee Securities Inc. and Dawson James\nSecurities, Inc.\n\n\nCopies of the United States prospectus may be obtained from Dawson James\nSecurities, Inc., Attn: Investment Banking, 925 South Federal Highway, 6th\nFloor, Boca Raton, FL 33432, telephone number (866) 928-0928. Copies of the\nCanadian prospectus may be obtained from Dundee Securities Corporation, 1\nAdelaide St. E., Suite 2700, Toronto, Ontario M4T 1J9; Attn: Equity Capital\nMarkets, E-mail: [email protected].\n\n\nThis press release shall not constitute an offer to sell or the\nsolicitation of an offer to buy these securities, and there shall be no sale\nof these securities in any state, province or jurisdiction in which such\noffer, solicitation or sale would be unlawful prior to registration or\nqualification under the securities laws of any such state, province or\njurisdiction.\n\n\nAbout NovaBay\n\n\nNovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on\ndeveloping innovative product candidates targeting the treatment or prevention\nof a wide range of infections in hospital and non-hospital environments.\nNovaBay has discovered and is developing a class of antimicrobial compounds,\nwhich it has named Aganocide compounds, which are based upon small molecules\nthat are generated by white blood cells that defend the body against invading\npathogens. NovaBay believes that Aganocide compounds could form a platform on\nwhich to create a variety of products to address differing needs in...